A registered Phase III study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase III
- Study design
- Interventional
- Evidence population
- Human clinical study registration
- Participants
- 230
- Population
- All · Adult
- Duration
- 2024-11-10 to 2027-11-30
- Intervention
- Faricimab; Drug
- Comparator
- Not reported
- Outcomes measured
- Change in best corrected visual acuity (BCVA) from baseline to an average of Week 52 and Week 56, as measured by the Ea…; Measured at Baseline, Week 20 and Week 56: 1. Efficacy on additional BCVA outcomes 2. Efficacy of anatomic outcome meas…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as Interventional.
Automated source check 98% · update recency 85%. These figures help sort records; they are not medical ratings.